Cellebrite DI (NASDAQ:CLBT) Price Target Lowered to $16.00 at JPMorgan Chase & Co.

Cellebrite DI (NASDAQ:CLBT) had its price objective reduced by JPMorgan Chase & Co. from $20.00 to $16.00 in a research note published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

CLBT has been the subject of a number of other reports. DA Davidson decreased their price objective on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a report on Friday. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Finally, Needham & Company LLC decreased their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.70.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $11.14 on Friday. The business has a 50 day simple moving average of $14.47 and a 200 day simple moving average of $14.03. Cellebrite DI has a 52-week low of $9.58 and a 52-week high of $19.98. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 50.64, a PEG ratio of 1.34 and a beta of 1.18.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.05. The firm had revenue of $131.14 million for the quarter, compared to the consensus estimate of $131.50 million. Cellebrite DI had a return on equity of 16.04% and a net margin of 11.43%. On average, analysts predict that Cellebrite DI will post 0.41 EPS for the current year.

Insider Transactions at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. The trade was a 2.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas E. Hogan sold 139,713 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the sale, the chief executive officer directly owned 790,548 shares in the company, valued at approximately $12,166,533.72. The trade was a 15.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 297,934 shares of company stock worth $4,631,972 in the last ninety days. Insiders own 5.70% of the company’s stock.

Institutional Trading of Cellebrite DI

Hedge funds have recently made changes to their positions in the business. Cooper Creek Partners Management LLC bought a new position in shares of Cellebrite DI during the 3rd quarter worth approximately $55,999,000. Capital International Investors acquired a new stake in Cellebrite DI during the 4th quarter valued at $41,073,000. Invesco Ltd. lifted its holdings in Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after purchasing an additional 2,054,644 shares during the last quarter. Weiss Asset Management LP boosted its position in Cellebrite DI by 3,485.3% during the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after purchasing an additional 1,846,851 shares during the period. Finally, Artisan Partners Limited Partnership bought a new position in Cellebrite DI during the fourth quarter worth $25,871,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.